Compare WORX & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WORX | AZTR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.9M |
| IPO Year | 2016 | 2023 |
| Metric | WORX | AZTR |
|---|---|---|
| Price | $1.07 | $0.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 1.5M | ★ 21.3M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.79 | 5.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,877,629.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.10 |
| 52 Week High | $1.69 | $1.40 |
| Indicator | WORX | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 71.72 | 47.60 |
| Support Level | $0.22 | $0.22 |
| Resistance Level | N/A | $0.23 |
| Average True Range (ATR) | 0.07 | 0.01 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 60.95 | 20.40 |
SCWorx Corp has developed and markets health information technology solutions and associated services that improve healthcare processes and information flow within hospitals. Its software platform enables healthcare providers to simplify, repair, and organize its data, allows the data to be utilized across multiple internal software applications and provides the basis for sophisticated data analytics. The company's solutions are designed to improve the flow of information quickly and accurately between the existing supply chain, electronic medical records, clinical systems, and patient billing functions. It operates in a single segment - health information technology solutions and services, located in a single geographic location - the United States.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.